Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction
Congestive Heart Failure, Renal Insufficiency
About this trial
This is an interventional treatment trial for Congestive Heart Failure
Eligibility Criteria
Inclusion Criteria: Decompensated heart failure hospitalization with at least 1 symptom and 1 sign of elevated filling pressures Admission estimated creatinine clearance =< 50 cc/min. Exclusion Criteria: Systolic blood pressure < 85 mm Hg Cardiogenic shock Volume depletion Myocardial infarction, unstable angina within last 30 days Significant valvular stenosis, hypertrophic/restrictive cardiomyopathy, or constrictive pericarditis Chronic hemodialysis Anticipated major procedure during hospitalization i.e. left heart catheterization, surgery, or transplantation Enrolled in another research protocol within last 30 days.
Sites / Locations
- Brigham and Women's Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Nesiritide + standard of care
Standard of care
Nesiritide: 1 mcg/kg bolus, followed by a continuous infusion at 0.005 mcg/kg/min which can be titrated every 3 hours by 0.005 mcg/kg/min to maximum dose of 0.03 mcg/kg/min until adequate diuresis achieved.
Standard of care until adequate diuresis achieved